CKLF2: A Potential Drug Target and Biomarker for Various Diseases

Target Name: CMTM2

NCBI ID: G146225

CMTM2

CKLF2: A Potential Drug Target and Biomarker for Various Diseases

CMTM2 (CKLF2-HUMAN) is a gene that encodes a protein known as CKLF2. CKLF2 is a key regulator of the cluster of co-regulated genes (CCGs) that are involved in various cellular processes, including cell adhesion, migration, and invasion. It is a protein that is expressed in various tissues and cells throughout the body, including the brain, pancreas, and gastrointestinal tract.

Recent studies have identified CKLF2 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because CKLF2 has been shown to play a role in the regulation of cellular processes that are often disrupted in these diseases, such as cell proliferation, migration, and invasion.

One of the key reasons for the potential of CKLF2 as a drug target is its involvement in the regulation of cell adhesion. CKLF2 is known to be involved in the formation of tight junctions, which are critical for maintaining the integrity of tissues and are often disrupted in diseases such as cancer. By targeting CKLF2, researchers may be able to develop new treatments for these diseases.

Another potential drug target for CKLF2 is its role in the regulation of neurodegenerative diseases. CKLF2 has been shown to be involved in the regulation of the aggregation of beta-amyloid peptides, which are a hallmark of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. By targeting CKLF2, researchers may be able to develop new treatments for these diseases.

In addition to its potential as a drug target, CKLF2 has also been identified as a potential biomarker for various diseases. For example, studies have shown that CKLF2 is often expressed in pancreatic cancer, and that its expression may be a useful diagnostic marker for this disease. Similarly, CKLF2 has been shown to be involved in the regulation of insulin secretion in the pancreas, and may be a useful biomarker for the development of insulin-dependent diabetes.

Overall, CKLF2 is a gene that has the potential to be a drug target and a biomarker for various diseases. Further research is needed to fully understand its role in these processes and to develop new treatments based on this understanding.

Protein Name: CKLF Like MARVEL Transmembrane Domain Containing 2

The "CMTM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CMTM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets